Literature DB >> 745011

The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

J Knoll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 745011     DOI： 10.1007/bf01246955

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  26 in total

1.  In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine.

Authors:  E A ZELLER; J BARSKY
Journal:  Proc Soc Exp Biol Med       Date:  1952-11

2.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

3.  Regional distribution of RNA and protein radioactivity in the rat brain after intraventricular application of labeled precursors.

Authors:  N Popov; W Pohle; B Lössner; S Schulzeck; S Schmidt; T Ott; H Matthies
Journal:  Acta Biol Med Ger       Date:  1973

4.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

5.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

6.  Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system.

Authors:  P G Guyenet; A F Javory; J C Beaujouan; B J Rossier; J Glowinski
Journal:  Brain Res       Date:  1975-02-07       Impact factor: 3.252

7.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

8.  [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa].

Authors:  F Gerstenbrand; P Prosenz
Journal:  Praxis       Date:  1965-11-18

9.  Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").

Authors:  E Varga; L Tringer
Journal:  Acta Med Acad Sci Hung       Date:  1967

10.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321
View more
  27 in total

1.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Chromatographic investigation and computer simulation of L-deprenyl metabolism.

Authors:  Z S Tarjányi; H Kalász; I Hollósi; M Báthori; T Bartók; J Lengyel; K Maguar; S Fürst
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 3.  Monoamine oxidase inhibitors revisited.

Authors:  D G Wells; A R Bjorksten
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

4.  Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

Authors:  H K Wayment; J O Schenk; B A Sorg
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 5.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

6.  Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.

Authors:  J P Finberg; M Tenne
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

Review 7.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

8.  Absence of "cheese effect" during deprenyl therapy: some recent studies.

Authors:  M Sandler; V Glover; A Ashford; G M Stern
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 9.  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.

Authors:  N W Milgram; G O Ivy; E Head; M P Murphy; P H Wu; W W Ruehl; P H Yu; D A Durden; B A Davis; I A Paterson
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

10.  Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

Authors:  V Glover; C J Pycock; M Sandler
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.